Drug Therapies

WEST PALM BEACH, Fla. — Treatment with fampridine may positively impact patients with multiple sclerosis who are recovering from optic neuritis, but more extensive clinical trials are required to fully assess its effectiveness, according to a poster at ACTRIMS.

For individuals with recent acute cervical spinal cord injuries, treatment with a novel neuroregenerative therapeutic was nonsuperior to placebo after 6 months, according to research published in The Lancet Neurology.

LOS ANGELES — Zorevunersen led to 75% to 80% seizure reduction in patients with Dravet syndrome, according to Barry S. Ticho, MD, PhD, FACC, chief medical officer of Stoke Therapeutics.

The European Medicines Agency has granted orphan drug designation to a small molecule intended to treat spinal and bulbar muscular atrophy, according to the manufacturer.

Health Canada has approved Daybue to treat Rett syndrome in patients aged 2 years and older, according to manufacturer Acadia Pharmaceuticals.

Early initiation and continuation of Kesimpta in those with relapsing MS was associated with lower rates of disability worsening up to 6 years compared with those who switched medication, according to a presentation at ECTRIMS 2024.

PHILADELPHIA — Treatment with lecanemab slowed the progression of a potential novel Alzheimer’s disease-related biomarker by 44% over 18 months compared with placebo, with the biomarker itself most correlating with tauopathy, data show.

The FDA has cleared an investigational new drug application for a phase 1/2 clinical trial to examine a novel, once-daily pill for the treatment of individuals with amyotrophic lateral sclerosis, according to the manufacturer.

DENVER — Efficacy of fumarates to treat multiple sclerosis was consistent across four racial and ethnic groups, particularly for Black, Hispanic and Asian persons, according to a poster at the American Academy of Neurology annual meeting.

The FDA’s approval of Leqembi in July 2023 triggered a wave of discussion in the medical community on how to prescribe and properly administer the amyloid-targeting antibody to treat those diagnosed with Alzheimer’s disease.